Neurocrine Biosciences
NBIX
#1457
Rank
NZ$20.26 B
Marketcap
$200.18
Share price
-4.42%
Change (1 day)
9.78%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2024 : NZ$0.42 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is NZ$0.42 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31NZ$0.67 B63.6%
2022-12-31NZ$0.41 B-35.78%
2021-12-31NZ$0.64 B12.84%
2020-12-31NZ$0.57 B-22.33%
2019-12-31NZ$0.73 B27.03%
2018-12-31NZ$0.57 B11.29%
2017-12-31NZ$0.52 B
2009-12-31NZ$15.87 M-40.17%
2008-12-31NZ$26.53 M1267.65%
2007-12-31NZ$1.93 M-97.45%
2006-12-31NZ$76.14 M-12.39%
2005-12-31NZ$86.91 M-6.22%
2004-12-31NZ$92.67 M65.35%
2003-12-31NZ$56.04 M269.65%
2002-12-31NZ$15.16 M10.71%
2001-12-31NZ$13.69 M56.82%
2000-12-31NZ$8.73 M47.22%
1999-12-31NZ$5.93 M4.2%
1998-12-31NZ$5.69 M106.46%
1997-12-31NZ$2.75 M21.75%
1996-12-31NZ$2.26 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
NZ$1.26 B 195.49%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$12.96 B 2,926.01%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$1 M-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$53.04 B 12,278.56%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$121.15 B 28,173.27%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$113.54 B 26,398.41%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.48 B 13.46%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$31.66 M-92.61%๐Ÿ‡บ๐Ÿ‡ธ USA